(CAH) Cardinal Health - Ratings and Ratios
Drugs, Medical Supplies, Surgical Kits, Gloves, Syringes
CAH EPS (Earnings per Share)
CAH Revenue
Description: CAH Cardinal Health
Cardinal Health Inc (NYSE:CAH) is a healthcare services and products company operating globally, providing customized solutions to various healthcare providers and patients. The companys diversified business model is reflected in its two main segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution.
Key Performance Indicators (KPIs) for Cardinal Health Inc include revenue growth, gross margin, and operating cash flow. With a market capitalization of approximately $39.4 billion, the companys financial health is crucial to its ability to invest in growth opportunities and return value to shareholders. The return on equity (RoE) of -50.14% indicates significant challenges in generating profits from shareholder equity, suggesting potential areas for improvement in operational efficiency or strategic direction.
The companys product and service offerings are broad, encompassing distribution of pharmaceuticals, medical supplies, and Cardinal Health branded products, as well as services like pharmacy management and supply chain solutions. This diversification can help mitigate risks associated with any single product or market. However, it also requires effective management across multiple business lines to maintain profitability.
From a valuation perspective, Cardinal Health Incs price-to-earnings (P/E) ratio of 25.85 and forward P/E of 17.51 suggest that the market expects earnings growth. The significant difference between the current and forward P/E ratios may indicate anticipated improvements in earnings. Analyzing these metrics in the context of industry peers and the broader healthcare sector can provide insights into whether CAH is undervalued or overvalued.
Cardinal Healths operational efficiency, ability to innovate, and capacity to manage its supply chain effectively will be critical in maintaining its competitive edge. The companys commitment to providing a wide range of healthcare products and services positions it as a significant player in the healthcare distribution and services market.
CAH Stock Overview
| Market Cap in USD | 35,886m |
| Sub-Industry | Health Care Distributors |
| IPO / Inception | 1987-12-31 |
CAH Stock Ratings
| Growth Rating | 95.4% |
| Fundamental | 72.8% |
| Dividend Rating | 52.5% |
| Return 12m vs S&P 500 | 13.3% |
| Analyst Rating | 4.12 of 5 |
CAH Dividends
| Dividend Yield 12m | 1.82% |
| Yield on Cost 5y | 6.14% |
| Annual Growth 5y | -4.84% |
| Payout Consistency | 96.7% |
| Payout Ratio | 24.7% |
CAH Growth Ratios
| Growth Correlation 3m | -88.6% |
| Growth Correlation 12m | 92.3% |
| Growth Correlation 5y | 95.5% |
| CAGR 5y | 33.18% |
| CAGR/Max DD 3y | 1.83 |
| CAGR/Mean DD 3y | 10.96 |
| Sharpe Ratio 12m | 1.80 |
| Alpha | 18.28 |
| Beta | 0.738 |
| Volatility | 19.84% |
| Current Volume | 1207.5k |
| Average Volume 20d | 2076.7k |
| Stop Loss | 145.7 (-3%) |
| Signal | -0.45 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (1.56b TTM) > 0 and > 6% of Revenue (6% = 13.35b TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -3.75pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -1.13% (prev -0.33%; Δ -0.80pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 2.40b > Net Income 1.56b (YES >=105%, WARN >=100%) |
| Net Debt (4.65b) to EBITDA (3.11b) ratio: 1.50 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.94 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (240.0m) change vs 12m ago -2.04% (target <= -2.0% for YES) |
| Gross Margin 3.67% (prev 3.26%; Δ 0.41pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 453.1% (prev 502.4%; Δ -49.24pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 10.77 (EBITDA TTM 3.11b / Interest Expense TTM 215.0m) >= 6 (WARN >= 3) |
Altman Z'' 0.12
| (A) -0.05 = (Total Current Assets 36.37b - Total Current Liabilities 38.90b) / Total Assets 53.12b |
| (B) 0.01 = Retained Earnings (Balance) 783.0m / Total Assets 53.12b |
| (C) 0.05 = EBIT TTM 2.32b / Avg Total Assets 49.12b |
| (D) 0.06 = Book Value of Equity 3.58b / Total Liabilities 55.76b |
| Total Rating: 0.12 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 72.80
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 4.56% = 2.28 |
| 3. FCF Margin 0.83% = 0.21 |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda 2.75 = -1.38 |
| 6. ROIC - WACC 33.57% = 12.50 |
| 7. RoE data missing |
| 8. Rev. Trend 70.86% = 5.31 |
| 9. EPS Trend 87.46% = 4.37 |
What is the price of CAH shares?
Over the past week, the price has changed by -0.01%, over one month by +0.44%, over three months by -7.19% and over the past year by +34.74%.
Is Cardinal Health a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CAH is around 173.97 USD . This means that CAH is currently undervalued and has a potential upside of +15.77% (Margin of Safety).
Is CAH a buy, sell or hold?
- Strong Buy: 9
- Buy: 2
- Hold: 5
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the CAH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 180.5 | 20.1% |
| Analysts Target Price | 180.5 | 20.1% |
| ValueRay Target Price | 191.7 | 27.6% |
Last update: 2025-09-10 04:33
CAH Fundamental Data Overview
CCE Cash And Equivalents = 3.87b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 23.2992
P/E Forward = 15.9744
P/S = 0.1612
P/B = 16.0657
P/EG = 1.5364
Beta = 0.74
Revenue TTM = 222.58b USD
EBIT TTM = 2.32b USD
EBITDA TTM = 3.11b USD
Long Term Debt = 7.98b USD (from longTermDebt, last quarter)
Short Term Debt = 550.0m USD (from shortTermDebt, last quarter)
Debt = 8.53b USD (Calculated: Short Term 550.0m + Long Term 7.98b)
Net Debt = 4.65b USD (from netDebt column, last quarter)
Enterprise Value = 40.54b USD (35.89b + Debt 8.53b - CCE 3.87b)
Interest Coverage Ratio = 10.77 (Ebit TTM 2.32b / Interest Expense TTM 215.0m)
FCF Yield = 4.56% (FCF TTM 1.85b / Enterprise Value 40.54b)
FCF Margin = 0.83% (FCF TTM 1.85b / Revenue TTM 222.58b)
Net Margin = 0.70% (Net Income TTM 1.56b / Revenue TTM 222.58b)
Gross Margin = 3.67% ((Revenue TTM 222.58b - Cost of Revenue TTM 214.41b) / Revenue TTM)
Tobins Q-Ratio = 11.31 (Enterprise Value 40.54b / Book Value Of Equity 3.58b)
Interest Expense / Debt = 0.87% (Interest Expense 74.0m / Debt 8.53b)
Taxrate = 25.32% (532.0m / 2.10b)
NOPAT = 1.73b (EBIT 2.32b * (1 - 25.32%))
Current Ratio = 0.94 (Total Current Assets 36.37b / Total Current Liabilities 38.90b)
Debt / EBITDA = 2.75 (Net Debt 4.65b / EBITDA 3.11b)
Debt / FCF = 4.61 (Debt 8.53b / FCF TTM 1.85b)
Total Stockholder Equity = -3.00b (last 4 quarters mean)
RoA = 2.94% (Net Income 1.56b, Total Assets 53.12b )
RoE = unknown (Net Income TTM 1.56b / Total Stockholder Equity -3.00b)
RoCE = 46.53% (Ebit 2.32b / (Equity -3.00b + L.T.Debt 7.98b))
RoIC = 40.75% (NOPAT 1.73b / Invested Capital 4.24b)
WACC = 7.18% (E(35.89b)/V(44.41b) * Re(8.73%)) + (D(8.53b)/V(44.41b) * Rd(0.87%) * (1-Tc(0.25)))
Shares Correlation 3-Years: -97.70 | Cagr: -1.16%
Discount Rate = 8.73% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.34% ; FCFE base≈2.42b ; Y1≈2.50b ; Y5≈2.83b
Fair Price DCF = 183.8 (DCF Value 43.89b / Shares Outstanding 238.8m; 5y FCF grow 3.48% → 3.0% )
EPS Correlation: 87.46 | EPS CAGR: 22.14% | SUE: 0.58 | # QB: False
Revenue Correlation: 70.86 | Revenue CAGR: 7.27%
Additional Sources for CAH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle